Hasten Biopharmaceuticals Expands Presence with Strategic Market Authorization Transfers Across Asia-Pacific

Hasten Biopharmaceutical Co., Ltd. has completed Market Authorization Transfers for 11 key pharmaceutical products in the Asia-Pacific region. This strategic move enhances Hasten's regional influence and commitment to providing high-quality, patient-centric healthcare solutions. The expansion aids in the treatment of chronic diseases like cardiovascular ailments and diabetes.

Hasten Biopharmaceutical Co., Ltd. has successfully finalized Market Authorization Transfers for 11 significant pharmaceutical products across several Asia-Pacific markets, including Malaysia and Singapore. Conducted by its affiliated entity, Hasten Biopharmaceutics (Asia) Co., Ltd., the transfers were completed in the first half of 2025. This step is a vital part of Hasten's regional expansion strategy.

The transferred products primarily target chronic diseases like cardiovascular and diabetes, involving well-known medications such as Actos® and Blopress®. Hasten plans to enhance its regulatory, manufacturing, and marketing capabilities across Asia-Pacific, supporting global biopharmaceutical partners in their regional activities and fostering joint accomplishments.

Company leaders emphasized the milestone's significance in their globalization strategy, reinforcing their mission to deliver high-quality medicines tuned to patient and healthcare system needs within the Asia-Pacific region. Hasten continues to pursue further market expansions, fortifying its position as a leader with robust commercialization capabilities.

(With inputs from agencies.)